Literature DB >> 16546547

Progress and hindrances in tuberculosis vaccine development.

T Mark Doherty1, Graham Rook.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16546547     DOI: 10.1016/S0140-6736(06)68389-X

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  5 in total

1.  Mycobacterium tuberculosis PE25/PPE41 protein complex induces activation and maturation of dendritic cells and drives Th2-biased immune responses.

Authors:  Wei Chen; Yige Bao; Xuerong Chen; Jeremy Burton; Xueli Gong; Dongqing Gu; Youjun Mi; Lang Bao
Journal:  Med Microbiol Immunol       Date:  2015-08-30       Impact factor: 3.402

2.  Adjuvant modulation of the cytokine balance in Mycobacterium tuberculosis subunit vaccines; immunity, pathology and protection.

Authors:  Else Marie Agger; Joseph P Cassidy; Joseph Brady; Karen S Korsholm; Carina Vingsbo-Lundberg; Peter Andersen
Journal:  Immunology       Date:  2008-01-12       Impact factor: 7.397

3.  Recombinant Mycobacterium bovis BCG expressing the chimeric protein of antigen 85B and ESAT-6 enhances the Th1 cell-mediated response.

Authors:  Ying Xu; Wei Liu; Hongbo Shen; Jingran Yan; Di Qu; Honghai Wang
Journal:  Clin Vaccine Immunol       Date:  2009-06-10

4.  PPE57 induces activation of macrophages and drives Th1-type immune responses through TLR2.

Authors:  Ying Xu; Enzhuo Yang; Qi Huang; Wenwen Ni; Cong Kong; Guoyuan Liu; Guanghua Li; Haibo Su; Honghai Wang
Journal:  J Mol Med (Berl)       Date:  2015-01-15       Impact factor: 4.599

5.  Induction of granulysin and perforin cytolytic mediator expression in 10-week-old infants vaccinated with BCG at birth.

Authors:  Patricia L Semple; Marcia Watkins; Virginia Davids; Alan M Krensky; Willem A Hanekom; Gilla Kaplan; Stanley Ress
Journal:  Clin Dev Immunol       Date:  2010-12-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.